U.S. halts Johnson and Johnson’s COVID-19 vaccine due to rare clot risk U.S. halts Johnson and Johnson’s COVID-19 vaccine due to rare clot risk
(REUTERS) – U.S. federal health agencies have paused the use of Johnson & Johnson’s COVID-19 vaccine. The decision follows the cases of six women... U.S. halts Johnson and Johnson’s COVID-19 vaccine due to rare clot risk

(REUTERS) – U.S. federal health agencies have paused the use of Johnson & Johnson’s COVID-19 vaccine. The decision follows the cases of six women under the age of 50 who developed rare blood clots after receiving their shots and deals a fresh setback in efforts to tackle the pandemic.

Johnson & Johnson (J&J) said it would delay the rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the U.S. South Africa has also suspended the use of J&J’s vaccine.

Acting U.S. Food and Drug Administration Commissioner Janet Woodcock said the agency expects the pause to be a matter of days and that it was meant to give them time to give information to healthcare providers on how to diagnose and treat the clots.

These moves come after European regulators said earlier this month they had found a possible link between AstraZeneca’s COVID-19 vaccine and similar rare blood clotting side effects. These side effects have led to the deaths of seven people as of April according to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

U.S Food and Drug Administration’s official Peter Marks said it was “plainly obvious” the J&J cases were “very similar” to the AstraZeneca ones. He said there had been no similar blood clot cases reported among recipients of the Moderna or Pfizer/BioNTech vaccines, which use different technology and accounted for the vast majority of U.S. vaccinations so far.

However, J&J’s single-dose shot and AstraZeneca’s low-cost vaccine are seen as vital weapons in the fight against a pandemic that has claimed more than three million lives.

Immunology experts echoed U.S. officials in underscoring that the risk posed by the J&J vaccine appeared extremely low.

“Even if causally linked to the vaccine: six cases with about seven million doses … is not something to panic about,” Dr. Amesh Adalja, an infectious disease expert at the Johns Hopkins Center for Health Security in Baltimore, said in an email, noting that the risk appears lower than that of clots from oral contraceptives.

He expressed concern that the pause could increase hesitancy to get vaccinated.

The FDA said there had been one reported death from the rare blood clotting condition among recipients of the J&J vaccine, while another person was in a critical condition.

The White House said appointments to receive the J&J shot were being rescheduled across the country to the other two authorized vaccines, and that there was enough supply of Pfizer and Moderna shots to hit President Joe Biden’s goal of administering 200 million shots during his first 100 days in office.

“There’s enough vaccine – that is basically 100 per cent unquestionable – for every single, solitary American,” Biden told reporters.

The Balance of Risks

J&J’s vaccine rollout has been limited by production issues. As of April 13, 7.2 million doses of the J&J vaccine had been administered in the United States compared with 185 million of the other two.

An advisory committee to the U.S. Centers for Disease Control and Prevention will meet on Wednesday to review the clotting cases and vote on recommendations for future use of the shot. The FDA will then review the analysis.

All six cases involved women between the ages of 18 and 48, with symptoms occurring six to 13 days after vaccination. The FDA said patients should watch for up to three weeks for symptoms including severe headache, abdominal pain, leg pain or shortness of breath.

In the cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets, or thrombocytopenia.

J&J, whose shares closed down 1.3 per cent, said it was working closely with regulators and noted no clear causal relationship had been established between the clots and its vaccine.

“To put this into perspective, it’s similar to the chance of being struck by lightning in any given year in the UK. On the other hand, the risks from COVID-19 are substantial,” said Ian Douglas from the London School of Hygiene & Tropical Medicine.

The J&J and AstraZeneca vaccines both use an adenovirus – a harmless cold virus – as a vector to deliver instructions for human cells to produce a protein found on the surface of the coronavirus, spurring the immune system to recognize and attack the actual virus.

Chinese and Russian COVID-19 vaccine developers CanSino Biological and Gamaleya Institute also rely on this approach. The Pfizer/BioNTech and Moderna vaccines use messenger RNA (mRNA) technology.

The European Medicines Agency (EMA) still recommends AstraZeneca’s COVID-19 vaccine, saying the benefits outweigh the risks. Several EU countries, however, have limited their use to certain age groups which have been linked to an increased risk.

As of April 4, the EMA said 169 cases of CVST and 53 of splanchnic vein thrombosis had been reported after vaccination with the AstraZeneca shot. About 34 million people had been given the shot in Europe by then.

J&J only began delivering its COVID-19 vaccine to European Union countries this week.

Benedict Rhodes